Citigroup’s Evolent Health EVH Stock Holding History

Citigroup’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-201,500	Closed	-$6.66M	–	5701
2023 Q4	$6.66M	Buy	+201,500	New	+$5.7M	﹤0.01%	1424
2021 Q4	–	Sell	-50,000	Closed	-$1.55M	–	5896
2021 Q3	$1.55M	Buy	+50,000	New	+$1.2M	﹤0.01%	2740
2019 Q3	–	Sell	-100,000	Closed	-$795K	–	7717
2019 Q2	$795K	Buy	+100,000	New	+$1.18M	﹤0.01%	3922

Other funds holding EVH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rubicon Founders Nashville, Tennessee $196M AUM 53.12% 1-Year Est. Return

Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Citigroup's EVH Position: Q2 2026 in Review

Citigroup reduced its Evolent Health (EVH) stake by 43% in Q2 2026, selling an estimated $1.33M and leaving 465,146 shares worth $2.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2756.

Citigroup first reported a position in EVH in Q2 2015 and has held it in 45 quarters since. The position peaked at $9.18M in Q2 2019. 199 funds tracked by Wall St. Rank hold EVH as of Q2 2026.

Citigroup held 465,146 shares of Evolent Health worth $2.52M as of Q2 2026.
Citigroup sold 346,949 Evolent Health shares in Q2 2026, an estimated $1.33M.
Evolent Health made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2756 holding.
Citigroup first reported a position in Evolent Health in Q2 2015 and has held it in 45 quarters since.
Citigroup's Evolent Health position peaked at $9.18M in Q2 2019.
199 funds tracked by Wall St. Rank held Evolent Health as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.